GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old

GlaxoSmithKline (NYSE:GSK) won FDA approval for the use of its Arnuity Ellipta inhaler as a once-daily therapy for the maintenance treatment of asthma in children as young as five years old.